Vietnam to cooperate with French firm to conduct clinical trials of XAV-19 COVID-19 treatment drug

Medical staff give COVID-19 treatment to patients (Photo: VNA)

Hanoi (VNA) – Deputy Minister of Health Tran
Van Thuan held an online working session with France’s Xenothera company on
cooperation to conduct the third phase of clinical trial of Xenothera-developed XAV-19 COVID-19
treatment drug and the transfer of XAV-19 production technology to
Vietnam.

The session drew leaders and experts of many departments of
the Vietnamese Health Ministry, as well as Xenothera President Odile Duvaux and
CEO Bernard Vanhove.

According to the Ministry of Health, XAV-19 is a drug based on polyclonal
antibodies that targets COVID-19 patients with moderate conditions.

The first and second
phases of XAV-19 clinical trials’ results showed that the drug is effective
and safe in preventing the virus to develop, neutralizing the virus and
reducing inflammation in patients.

The third phase of XAV-19 clinical trials is being conducted in some European
countries.

Odile Duvaux said that her company is willing to cooperate
with Vietnam in implementing the third phase of the trials, and to engage in further discussions on the transfer of the drug production technology to
Vietnam.

In May this year, the Ministry of Health and Solidarity of
France ordered 30,000 doses of XAV-19 from Xenothera.

Deputy Minister Thuan affirmed Vietnam’s readiness to cooperate with Xenothera
in implementing the third phase clinical trials of XAV-19 and receiving
technical transfer from the firm.

Following the working session, a Vietnamese firm discussed with specific contents in preparation for the signing of a memorandum of understanding on cooperating in
the third-phase clinical trials of XAV-19 and technology transfer from the French firm./.